MENU
+Compare
HROW
Stock ticker: NASDAQ
AS OF
Aug 14 closing price
Price
$40.01
Change
+$3.51 (+9.62%)
Capitalization
1.48B

HROW stock forecast, quote, news & analysis

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U... Show more

HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. HROW showed earnings on August 11, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for HROW with price predictions
Aug 14, 2025

HROW sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for HROW moved above the 200-day moving average on August 12, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on HROW as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HROW just turned positive on August 13, 2025. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

HROW moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 210 cases where HROW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HROW broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HROW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.851) is normal, around the industry mean (19.695). P/E Ratio (0.000) is within average values for comparable stocks, (72.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.837). HROW has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (6.333) is also within normal values, averaging (40.299).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.73B. The market cap for tickers in the group ranges from 5.57K to 67.83B. ZTS holds the highest valuation in this group at 67.83B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 8%. For the same Industry, the average monthly price growth was 15%, and the average quarterly price growth was 79%. TLRY experienced the highest price growth at 81%, while OWPC experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was 213%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 69
Price Growth Rating: 54
SMR Rating: 84
Profit Risk Rating: 92
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a pharmaceutical company

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
102 Woodmont Boulevard
Phone
+1 615 733-4730
Employees
315
Web
https://www.harrow.com